Literature DB >> 15093564

Development of an ELISA for the detection of autoantibodies to BP230.

Arno Kromminga1, Cassian Sitaru, Christine Hagel, Susanne Herzog, Detlef Zillikens.   

Abstract

Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease associated with autoantibodies against the transmembrane hemidesmosomal protein BP180/collagen type XVII and the intracellular plaque protein BP230. The aim of the present study was to develop an ELISA system for the detection of circulating autoantibodies to BP230. We generated five overlapping cDNA constructs covering the entire length of BP230 and expressed them in baculovirus-infected Sf21 insect cells. ELISA reactivity against BP230 was found in 63% of 56 BP patients' sera; the specificity of the ELISA was 93%. Epitope mapping studies showed that the fragment representing the C-terminal portion of BP230 was by far the most frequent target within the molecule. This ELISA provides a useful tool for the detection of autoantibodies to BP230 in BP and other diseases associated with an autoimmune response to this protein.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15093564     DOI: 10.1016/j.clim.2003.12.007

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  16 in total

Review 1.  What's new in blistering disorders?

Authors:  Paru Chaudhari; M Peter Marinkovich
Journal:  Curr Allergy Asthma Rep       Date:  2007-07       Impact factor: 4.806

Review 2.  The diagnosis and treatment of autoimmune blistering skin diseases.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  Dtsch Arztebl Int       Date:  2011-06-10       Impact factor: 5.594

Review 3.  Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.

Authors:  Kyle T Amber; Dedee F Murrell; Enno Schmidt; Pascal Joly; Luca Borradori
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

4.  Diagnosis and clinical severity markers of bullous pemphigoid.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  F1000 Med Rep       Date:  2009-02-24

Review 5.  The pathophysiology of bullous pemphigoid.

Authors:  Michael Kasperkiewicz; Detlef Zillikens
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

6.  A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid.

Authors:  Kelly A N Messingham; Megan H Noe; Marisa A Chapman; George J Giudice; Janet A Fairley
Journal:  J Immunol Methods       Date:  2009-05-05       Impact factor: 2.303

7.  Serological diagnosis of autoimmune bullous skin diseases: prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy.

Authors:  Nina van Beek; Kristin Rentzsch; Christian Probst; Lars Komorowski; Michael Kasperkiewicz; Kai Fechner; Inga M Bloecker; Detlef Zillikens; Winfried Stöcker; Enno Schmidt
Journal:  Orphanet J Rare Dis       Date:  2012-08-09       Impact factor: 4.123

8.  Usefulness of Enzyme-linked Immunosorbent Assay Using Recombinant BP180 and BP230 for Serodiagnosis and Monitoring Disease Activity of Bullous Pemphigoid.

Authors:  Eui Hyung Lee; Yeon Hee Kim; Sinyoung Kim; Song-Ee Kim; Soo-Chan Kim
Journal:  Ann Dermatol       Date:  2012-02-02       Impact factor: 1.444

9.  Prevalence of pemphigus and pemphigoid autoantibodies in the general population.

Authors:  Wiebke Prüßmann; Jasper Prüßmann; Hiroshi Koga; Andreas Recke; Hiroaki Iwata; David Juhl; Siegfried Görg; Reinhard Henschler; Takashi Hashimoto; Enno Schmidt; Detlef Zillikens; Saleh M Ibrahim; Ralf J Ludwig
Journal:  Orphanet J Rare Dis       Date:  2015-05-15       Impact factor: 4.123

10.  Association of autoantibodies to BP180 with disease activity in Greek patients with bullous pemphigoid.

Authors:  Aikaterini Patsatsi; Aikaterini Kyriakou; Aikaterini Pavlitou-Tsiontsi; Anastasia Giannakou; Dimitrios Sotiriadis
Journal:  Clin Dev Immunol       Date:  2012-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.